# EDGAR Filing Document

**Accession Number:** 0000001800
**File Stem:** 0001104659-26-020509
**Filing Date:** 2026-2
**Character Count:** 80984
**Document Hash:** 62bf3ff846d0fd77f52d140cf1cfee29
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-020509.hdr.sgml**: 20260226

**ACCESSION NUMBER**: 0001104659-26-020509

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20260223

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260226

**DATE AS OF CHANGE**: 20260226

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ABBOTT LABORATORIES
- **CENTRAL INDEX KEY:** 0000001800
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 360698440
- **STATE OF INCORPORATION:** IL
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-02189
- **FILM NUMBER:** 26688403

**BUSINESS ADDRESS:**
- **STREET 1:** 100 ABBOTT PARK ROAD
- **CITY:** ABBOTT PARK
- **STATE:** IL
- **ZIP:** 60064-3500
- **BUSINESS PHONE:** 2246676100

**MAIL ADDRESS:**
- **STREET 1:** 100 ABBOTT PARK ROAD
- **CITY:** ABBOTT PARK
- **STATE:** IL
- **ZIP:** 60064-3500

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of**

**The Securities Exchange Act of 1934**

**February 23, 2026**

Date of Report (Date of earliest event reported)

**ABBOTT LABORATORIES**

(Exact name of Registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Illinois** | **1-2189** | **36-0698440** |
| (State or other Jurisdiction of | (Commission file number) | (I.R.S. Employer Identification |
| Incorporation) |  | Number) |

---

**100 Abbott Park Road**

**Abbott Park, Illinois 60064-6400**

(Address of principal executive offices) (Zip code)

Registrant's telephone number, including area code: **(224) 667-6100**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

◻&nbsp;&nbsp;&nbsp;&nbsp; Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

◻&nbsp;&nbsp;&nbsp;&nbsp; Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

◻&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

◻&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities Registered Pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of Each Class** | **Trading<br> Symbol(s)** | **Name of Each Exchange<br> on Which Registered** |
| Common Shares, Without Par Value | ABT | New York Stock Exchange<br> NYSE Texas |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

**Item 1.01. Entry into a Material Definitive Agreement**

On February 23, 2026, Abbott Laboratories ("Abbott") entered into a pricing agreement (the "Pricing Agreement"), dated February 23, 2026, by and among Abbott, Morgan Stanley & Co. LLC, Barclays Capital Inc., BofA Securities, Inc. and J.P. Morgan Securities LLC, for themselves and as representatives of the several other underwriters named therein (the "Underwriters"), pursuant to which Abbott agreed to issue and sell $20,000,000,000 aggregate principal amount of senior notes, consisting of $1,000,000,000 aggregate principal amount of its Floating Rate Notes due 2029 (the "Floating Rate Notes"), $2,250,000,000 aggregate principal amount of its 3.700% Notes due 2029 (the "2029 Notes"), $2,500,000,000 aggregate principal amount of its 4.000% Notes due 2031 (the "2031 Notes"), $2,750,000,000 aggregate principal amount of its 4.300% Notes due 2033 (the "2033 Notes"), $3,750,000,000 aggregate principal amount of its 4.650% Notes due 2036 (the "2036 Notes"), $2,000,000,000 aggregate principal amount of its 4.750% Notes due 2038 (the "2038 Notes"), $3,750,000,000 aggregate principal amount of its 5.500% Notes due 2056 (the "2056 Notes") and $2,000,000,000 aggregate principal amount of its 5.600% Notes due 2066 (the "2066 Notes" and, together with the 2029 Notes, the 2031 Notes, the 2033 Notes, the 2036 Notes, the 2038 Notes and the 2056 Notes, the "Fixed Rate Notes" and the Fixed Rate Notes together with the Floating Rate Notes, the "Notes").

The Pricing Agreement includes customary representations, warranties and covenants by Abbott. It also provides for customary indemnification by each of Abbott and the respective Underwriters against certain liabilities and customary contribution provisions in respect of those liabilities.

Each series of Notes were offered pursuant to the Prospectus Supplement dated February 23, 2026, filed with the Securities and Exchange Commission (the "SEC") on February 25, 2026 (the "Prospectus Supplement"), and the Prospectus dated February 23, 2026, filed as part of the shelf registration statement (File No. 333-293636) that became effective under the Securities Act of 1933, as amended, when filed with the SEC on February 23, 2026. The terms of the Notes are further described in the Prospectus Supplement. The closing of the sale of the Notes is expected to occur on March 9, 2026, subject to customary closing conditions.

Abbott intends to use the net proceeds from the Notes offering, together with cash on hand and/or additional borrowings (which may include, among other things, issuances of commercial paper), to fund the consideration for the acquisition of Exact Sciences Corporation ("Exact Sciences"), to repay certain indebtedness of Exact Sciences, to pay related fees and expenses, and for general corporate purposes, which may include, without limitation, the repayment of indebtedness.

Please refer to the Prospectus Supplement for additional information regarding the Notes offering and the terms and conditions of the Notes. The foregoing summary of the Pricing Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Pricing Agreement filed as Exhibit 1.1 hereto and incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| [1.1](tm264905d7_ex1-1.htm) | [Pricing Agreement.](tm264905d7_ex1-1.htm) |
| 104 | Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document). |

---

**Forward-Looking Statements**

This communication contains forward-looking statements about, among other things, the proposed acquisition of Exact Sciences by Abbott, the expected closing date of the offering of the Notes and the use of proceeds therefrom. Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Abbott cautions that these forward-looking statements are subject to risks and uncertainties, including the risks related to the proposed acquisition of Exact Sciences, that may cause actual results to differ materially from those indicated in the forward-looking statements.

You should carefully consider the foregoing and the other risks and uncertainties that affect the business of Abbott described in the "Risk Factors" section in each of the Prospectus Supplement, Abbott's Annual Report on Form 10-K for the year ended December 31, 2025, and Abbott's other reports filed with the SEC. Free copies of these documents may be obtained from the SEC's website at www.sec.gov. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Abbott undertakes no obligation, and does not intend, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments or otherwise, except as required by law.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **ABBOTT LABORATORIES** | **ABBOTT LABORATORIES** |
| Date: February 26, 2026 | By: | /s/ Philip P. Boudreau |
|  |  | Philip P. Boudreau |
|  |  | Executive Vice President, Finance and Chief Financial Officer |

---

## Exhibit 1.1

**Exhibit 1.1**

**Pricing Agreement**

Morgan Stanley & Co. LLC<br> 1585 Broadway<br> New York, New York 10036

and

Barclays Capital Inc.

745 Seventh Avenue

New York, New York 10019

and

BofA Securities, Inc.

One Bryant Park

New York, New York 10036

and

J.P. Morgan Securities LLC

270 Park Avenue

New York, New York 10017

As Representatives of the several<br> Underwriters named in Schedule I hereto

February 23, 2026

Ladies and Gentlemen:

Abbott Laboratories, an Illinois corporation (the "**Company**"), proposes, subject to the terms and conditions stated herein and in the Underwriting Agreement, dated March 5, 2015 (the "**Underwriting Agreement**"), between the Company and the Representatives of the several Underwriters to issue and sell to the Underwriters named in Schedule I hereto (the "**Underwriters**") the Securities specified in Schedule II hereto (the "**Designated Securities**"). Each of the provisions of the Underwriting Agreement is incorporated herein by reference in its entirety and shall be deemed to be a part of this Agreement to the same extent as if such provisions had been set forth in full herein; and each of the representations and warranties set forth therein shall be deemed to have been made at and as of the date of this Pricing Agreement, except that each representation and warranty which refers to the Prospectus in Section 1 of the Underwriting Agreement shall be deemed to be a representation or warranty as of the S-3 Filing Date (as defined below) in relation to the Prospectus (as therein defined), and also a representation and warranty as of the date of this Pricing Agreement in relation to the Prospectus as amended or supplemented relating to the Designated Securities which are the subject of this Pricing Agreement. Each reference to the Representatives herein and in the provisions of the Underwriting Agreement so incorporated by reference shall be deemed to refer to you. Unless otherwise defined herein, terms defined in the Underwriting Agreement are used herein as therein defined. The Representatives designated to act on behalf of the Representatives and on behalf of each of the Underwriters of the Designated Securities pursuant to Section 10 of the Underwriting Agreement and the address of the Representatives referred to in such Section 10 are set forth at the end of Schedule II hereto. The Permitted Free Writing Prospectuses relating to the Designated Securities are attached hereto as Schedule III.

The Company has filed with the Commission an automatic shelf registration statement, as defined in Rule 405 under the Securities Act, on Form S-3 (File No. 333-293636) on February 23, 2026 (the "**S-3 Filing Date**") relating to the Securities. References to the "Registration Statement," as used with respect to the Designated Securities, means the registration statement with such file number.

An amendment to the Registration Statement, or a supplement to the Prospectus, as the case may be, relating to the Designated Securities, in the form heretofore delivered to you is now proposed to be filed with the Commission.

Subject to the terms and conditions set forth herein and in the Underwriting Agreement incorporated herein by reference, the Company agrees to issue and sell to each of the Underwriters, and each of the Underwriters agrees, severally and not jointly, to purchase from the Company, at the time and place and at the purchase price to the Underwriters set forth in Schedule II hereto, the principal amount of Designated Securities set forth opposite the name of such Underwriter in Schedule I hereto.

The offering of the Designated Securities is being made in connection with the Agreement and Plan of Merger (the "**Merger Agreement**"), dated as of November 19, 2025, by and among the Company, Exact Sciences Corporation, a Delaware corporation ("**Exact Sciences**"), and Badger Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Company ("**Merger Sub**"), pursuant to which, among other things, Merger Sub will be merged with and into Exact Sciences (the "**Merger**"), with Exact Sciences surviving the Merger as a direct, wholly owned subsidiary of the Company.

The representation set forth in Section 1(p) of the Underwriting Agreement shall be replaced in its entirety with the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(p) The Company and its subsidiaries (i) make and keep accurate books and records in all material respects and (ii) maintain internal accounting controls which provide reasonable assurance that (A) transactions are executed in accordance with management's authorization, (B) transactions are recorded as necessary to permit preparation of its financial statements and to maintain accountability for its assets, (C) access to its assets is permitted only in accordance with management's authorization and (D) the reported accountability for its assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any difference;

The representation set forth in Section 1(q) of the Underwriting Agreement shall be replaced in its entirety with the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(q) The Company has established, maintains and will maintain disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) which are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported in accordance with the Exchange Act and the rules and regulations thereunder in all material respects. The Company has carried out and will carry out evaluations, under the supervision and with the participation of the Company's management, of the effectiveness of the design and operation of the Company's disclosure controls and procedures in accordance with Rule 13a-15 of the Exchange Act;

The representation set forth in Section 1(s) of the Underwriting Agreement shall be replaced in its entirety with the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(s) Ernst & Young LLP has audited and reported on certain financial statements of the Company and its subsidiaries and the effectiveness of the Company's internal control over financial reporting. Ernst & Young LLP is an independent registered public accounting firm with respect to the Company and its subsidiaries as required by the Securities Act and the Exchange Act and the rules and regulations of the Commission and the Public Company Accounting Oversight Board;

The representation set forth in Section 1(u) of the Underwriting Agreement shall be replaced in its entirety with the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(u) Neither the Company nor any of its subsidiaries nor, to the knowledge of the Company, any director, officer, agent, employee or affiliate of the Company or any of its subsidiaries is currently subject to or the target of any sanctions administered or enforced by the Office of Foreign Assets Control of the U.S. Treasury Department, the U.S. Department of State, the United Nations Security Council, the European Union, His Majesty's Treasury, or other relevant sanctions authority in a jurisdiction material to the Company and its subsidiaries taken as a whole (collectively, "**Sanctions**"); nor is the Company or any of its subsidiaries located, organized or resident in a country that is the subject of Sanctions (including, without limitation, the so-called Donetsk People's Republic, the so-called Luhansk People's Republic, or any other Covered Region of Ukraine identified pursuant to Executive Order 14065, Crimea, Cuba, Iran and North Korea); and the Company will not directly or, to the knowledge of the Company, indirectly use the proceeds of the offering, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity, for the purpose of financing the activities of any person, or in any country or territory, that at the time of such financing is the subject or target of Sanctions.

Section 5(c)(vi) of the Underwriting Agreement shall be replaced in its entirety with the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi) The Indenture has been duly authorized, executed and delivered by the Company;

Section 5(c)(ix) of the Underwriting Agreement shall be deleted in its entirety.

The opinion to be delivered pursuant to Section 5(c) of the Underwriting Agreement shall be delivered by Jessica Paik, Divisional Vice President, Associate General Counsel, and Assistant Secretary of the Company; and the opinion to be delivered pursuant to Section 5(d) of the Underwriting Agreement shall be delivered by Wachtell, Lipton, Rosen & Katz, special counsel for the Company in a form agreed between Wachtell, Lipton, Rosen & Katz and the Representatives.

The letters to be delivered pursuant to Section 5(e) of the Underwriting Agreement shall be delivered by Ernst & Young LLP, the independent accountant of the Company, to the effect set forth in Annex II to the Underwriting Agreement.

**<u>Agreement and Acknowledgment with Respect to the Exercise of Bail-in Powers:</u>** In addition to the other agreements contained in the Underwriting Agreement, the Company agrees with each of the Underwriters that:

Notwithstanding and to the exclusion of any other term of this Pricing Agreement or any other agreements, arrangements or understanding between the Representatives and the Company, each of the parties to this Pricing Agreement acknowledges and accepts that a BRRD Liability arising under this Pricing Agreement may be subject to the exercise of Bail-in Powers by the Relevant Resolution Authority, and acknowledges, accepts, and agrees to be bound by:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) the effect of the exercise of Bail-in Powers by the Relevant Resolution Authority in relation to any BRRD Liability of an Underwriter to any other party under this Pricing Agreement, that (without limitation) may include and result in any of the following, or some combination thereof:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) the reduction of all, or a portion, of the BRRD Liability or outstanding amounts due thereon;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) the conversion of all, or a portion of, the BRRD Liability into shares, other securities or other obligations of an Underwriter or another person, (and the issue to or conferral on such other party to this Pricing Agreement of such shares, securities or obligations);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) the cancellation of the BRRD Liability;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) the amendment or alteration of any interest, if applicable, thereon, the maturity or the dates on which any payments are due, including by suspending payment for a temporary period; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) the variation of the terms of this Pricing Agreement, as deemed necessary by the Relevant Resolution Authority, to give effect to the exercise of Bail-in Powers by the Relevant Resolution Authority.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) As used in this Pricing Agreement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) "Bail-in Legislation" means in relation to a member state of the European Economic Area which has implemented, or which at any time implements, the BRRD, the relevant implementing law, regulation, rule or requirement as described in the EU Bail-in Legislation Schedule from time to time.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) "Bail-in Powers" means any Write-down and Conversion Powers as defined in the EU Bail-in Legislation Schedule, in relation to the relevant Bail-in Legislation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) "BRRD" means Directive 2014/59/EU establishing a framework for the recovery and resolution of credit institutions and investment firms.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) "BRRD Liability" means a liability in respect of which the relevant Write-down and Conversion Powers in the applicable Bail-in Legislation may be exercised.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) "EU Bail-in Legislation Schedule" means the document described as such, then in effect, and published by the Loan Market Association (or any successor person) from time to time at http://www.lma.eu.com.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi) "Relevant Resolution Authority" means the resolution authority with the ability to exercise any Bail-in Powers.

If the foregoing is in accordance with your understanding, please sign and return to us counterparts hereof, and upon acceptance hereof by you, on behalf of each of the Underwriters, this letter and such acceptance hereof, including the provisions of the Underwriting Agreement incorporated herein by reference, shall constitute a binding agreement between each of the Underwriters and the Company. It is understood that your acceptance of this letter on behalf of each of the Underwriters is or will be pursuant to the authority set forth in a form of Agreement among Underwriters, the form of which shall be submitted to the Company for examination upon request, but without warranty on the part of the Representatives as to the authority of the signers thereof.

**<u>Recognition of the U.S. Special Resolution Regimes</u>** **<u>:</u>** In addition to the other agreements contained in the Underwriting Agreement, the Company agrees with each of the Underwriters that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime,
the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to
the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and
obligation, were governed by the laws of the United States or a state of the United States.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) In the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding
under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted
to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement
were governed by the laws of the United States or a state of the United States.

For purposes of this Section a "**BHC Act Affiliate**" has the meaning assigned to the term "affiliate" in, and shall be interpreted in accordance with, 12 U.S.C. § 1841(k). "**Covered Entity**" means any of the following: (i) a "covered entity" as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 252.82(b); (ii) a "covered bank" as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 47.3(b); or (iii) a "covered FSI" as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 382.2(b). "**Default Right**" has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. §§ 252.81, 47.2 or 382.1, as applicable. "**U.S. Special Resolution Regime**" means each of (i) the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.

---

| | | |
|:---|:---|:---|
| Very truly yours, | Very truly yours, | Very truly yours, |
| Abbott Laboratories | Abbott Laboratories | Abbott Laboratories |
| By: | /s/ James R. Wenner | /s/ James R. Wenner |
|  | Name: | James R. Wenner |
|  | Title: | Vice President, Treasurer |

---

*[Signature Page – Pricing Agreement]*

---

| | |
|:---|:---|
| Accepted as of the date hereof: | Accepted as of the date hereof: |
| Morgan Stanley & Co. LLC | Morgan Stanley & Co. LLC |
| By: | /s/ Thomas Hadley |
|  | On behalf of each of the Underwriters |

---

---

| | |
|:---|:---|
| Accepted as of the date hereof: | Accepted as of the date hereof: |
| Barclays Capital Inc. | Barclays Capital Inc. |
| By: | /s/ James Gutow |
|  | On behalf of each of the Underwriters |
| Accepted as of the date hereof: | Accepted as of the date hereof: |
| BofA Securities, Inc. | BofA Securities, Inc. |
| By: | /s/ Douglas Muller |
|  | On behalf of each of the Underwriters |

---

---

| | |
|:---|:---|
| Accepted as of the date hereof: | Accepted as of the date hereof: |
| J.P. Morgan Securities LLC | J.P. Morgan Securities LLC |
| By: | /s/ Saee Athalye |
|  | On behalf of each of the Underwriters |

---

*[Signature Page – Pricing Agreement]*

**SCHEDULE I**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Underwriter** | **Principal<br> Amount of<br> Floating Rate<br> Notes due<br> 2029** | **Principal<br> Amount of<br> Notes due<br> 2029** | **Principal<br> Amount of<br> Notes due<br> 2031** | **Principal<br> Amount of<br> Notes due<br> 2033** | **Principal<br> Amount of<br> Notes due<br> 2036** | **Principal<br> Amount of<br> Notes due<br> 2038** | **Principal<br> Amount of<br> Notes due<br> 2056** | **Principal<br> Amount of<br> Notes due<br> 2066** |
| Morgan Stanley & Co. LLC | $265000000 | $596250000 | $662500000 | $728750000 | $993750000 | $530000000 | $993750000 | $530000000 |
| Barclays Capital Inc. | 120000000 | 270000000 | 300000000 | 330000000 | 450000000 | 240000000 | 450000000 | 240000000 |
| BofA Securities, Inc. | 120000000 | 270000000 | 300000000 | 330000000 | 450000000 | 240000000 | 450000000 | 240000000 |
| J.P. Morgan Securities LLC | 120000000 | 270000000 | 300000000 | 330000000 | 450000000 | 240000000 | 450000000 | 240000000 |
| BNP Paribas Securities Corp. | 45000000 | 101250000 | 112500000 | 123750000 | 168750000 | 90000000 | 168750000 | 90000000 |
| Citigroup Global Markets Inc. | 45000000 | 101250000 | 112500000 | 123750000 | 168750000 | 90000000 | 168750000 | 90000000 |
| Deutsche Bank Securities Inc. | 45000000 | 101250000 | 112500000 | 123750000 | 168750000 | 90000000 | 168750000 | 90000000 |
| MUFG Securities Americas Inc. | 45000000 | 101250000 | 112500000 | 123750000 | 168750000 | 90000000 | 168750000 | 90000000 |
| SG Americas Securities, LLC | 45000000 | 101250000 | 112500000 | 123750000 | 168750000 | 90000000 | 168750000 | 90000000 |
| HSBC Securities (USA) Inc. | 25000000 | 56250000 | 62500000 | 68750000 | 93750000 | 50000000 | 93750000 | 50000000 |
| Mizuho Securities USA LLC | 25000000 | 56250000 | 62500000 | 68750000 | 93750000 | 50000000 | 93750000 | 50000000 |
| Santander US Capital Markets LLC | 25000000 | 56250000 | 62500000 | 68750000 | 93750000 | 50000000 | 93750000 | 50000000 |
| Standard Chartered Bank | 25000000 | 56250000 | 62500000 | 68750000 | 93750000 | 50000000 | 93750000 | 50000000 |
| Goldman Sachs & Co. LLC | 10000000 | 22500000 | 25000000 | 27500000 | 37500000 | 20000000 | 37500000 | 20000000 |
| RBC Capital Markets, LLC | 10000000 | 22500000 | 25000000 | 27500000 | 37500000 | 20000000 | 37500000 | 20000000 |
| Siebert Williams Shank & Co., LLC | 10000000 | 22500000 | 25000000 | 27500000 | 37500000 | 20000000 | 37500000 | 20000000 |
| Academy Securities, Inc. | 5000000 | 11250000 | 12500000 | 13750000 | 18750000 | 10000000 | 18750000 | 10000000 |
| BBVA Securities Inc. | 5000000 | 11250000 | 12500000 | 13750000 | 18750000 | 10000000 | 18750000 | 10000000 |
| ING Financial Markets LLC | 5000000 | 11250000 | 12500000 | 13750000 | 18750000 | 10000000 | 18750000 | 10000000 |
| U.S. Bancorp Investments, Inc. | 5000000 | 11250000 | 12500000 | 13750000 | 18750000 | 10000000 | 18750000 | 10000000 |
| Total | $1000000000 | $2250000000 | $2500000000 | $2750000000 | $3750000000 | $2000000000 | $3750000000 | $2000000000 |

---

**SCHEDULE II-A**

---

| | |
|:---|:---|
| **Title of Notes:** | Floating Rate Notes due 2029 (the "Floating Rate Notes") |
| **Aggregate principal amount:** | $1000000000 |
| **Pricing Effective Time:** | 5:10 p.m., New York City time, February 23, 2026 |
| **Price to Public:** | 100.000% of the principal amount of the Floating Rate Notes, plus accrued interest from March 9, 2026 (if any). |
| **Purchase Price by Underwriters:** | 99.750% of the principal amount of the Floating Rate Notes, plus accrued interest from March 9, 2026 (if any). |
| **Method of and specified funds for payment of purchase price:** | By wire transfer to a bank account specified by the Company in immediately available funds |
| **Indenture:** | Indenture, dated as of March 10, 2015, between the Company and U.S. Bank National Association, as Trustee |
| **Maturity:** | March 9, 2029 |
| **Interest Rate:** | The Floating Rate Notes will bear interest at a floating rate equal to a benchmark rate, which will initially be Compounded SOFR (as defined in the Prospectus Supplement under "Description of Notes"), plus a spread of 0.500% per year, accruing from March 9, 2026. |
| **Interest Payment Dates:** | March 9, June 9, September 9 and December 9, commencing June 9, 2026. |
| **Redemption Provisions:** | As set forth in the Prospectus Supplement under "Description of Notes" |
| **Sinking Fund Provisions:** | No sinking fund provisions |
| **Defeasance provisions:** | Sections 13.2 and 13.3 of the Indenture shall be applicable to the Floating Rate Notes |
| **Time of Delivery:** | March 9, 2026 |
| **Closing Location for Delivery of Securities:** | The Depository Trust Company<br> 55 Water Street<br> New York, New York 10041 |

---

---

| | |
|:---|:---|
| **Names and addresses of Representatives:** |  |
| Designated Representatives: | Morgan Stanley & Co. LLC<br> Barclays Capital Inc.<br> BofA Securities, Inc.<br> J.P. Morgan Securities LLC |
| Address for Notices, etc.: | c/o<br> Morgan Stanley & Co. LLC<br> 1585 Broadway, 29th Floor<br> New York, New York 10036<br> Attn: Investment Banking Division (fax: (212) 507-8999)<br>BofA Securities, Inc<br> 114 West 47th Street<br> NY8-114-07-01<br> New York, NY10036<br> Attention: High Grade Debt Capital Markets Transaction Management/Legal<br> Fax: 212-901-7881 |

---

**SCHEDULE II-B**

---

| | |
|:---|:---|
| **Title of Notes:** | 3.700% Notes due 2029 (the "2029 Notes") |
| **Aggregate principal amount:** | $2250000000 |
| **Pricing Effective Time:** | 5:10 p.m., New York City time, February 23, 2026 |
| **Price to Public:** | 99.873% of the principal amount of the 2029 Notes, plus accrued interest from March 9, 2026 (if any). |
| **Purchase Price by Underwriters:** | 99.623% of the principal amount of the 2029 Notes, plus accrued interest from March 9, 2026 (if any). |
| **Method of and specified funds for payment of purchase price:** | By wire transfer to a bank account specified by the Company in immediately available funds |
| **Indenture:** | Indenture, dated as of March 10, 2015, between the Company and U.S. Bank National Association, as Trustee |
| **Maturity:** | March 9, 2029 |
| **Interest Rate:** | 3.700% |
| **Interest Payment Dates:** | Semiannually on March 9 and September 9, commencing September 9, 2026. |
| **Redemption Provisions:** | As set forth in the Prospectus Supplement under "Description of Notes" |
| **Sinking Fund Provisions:** | No sinking fund provisions |
| **Defeasance provisions:** | Sections 13.2 and 13.3 of the Indenture shall be applicable to the 2029 Notes |
| **Time of Delivery:** | March 9, 2026 |
| **Closing Location for Delivery of Securities:** | The Depository Trust Company<br> 55 Water Street<br> New York, New York 10041 |
| **Names and addresses of Representatives:** |  |
| Designated Representatives: | Morgan Stanley & Co. LLC<br> Barclays Capital Inc.<br> BofA Securities, Inc.<br> J.P. Morgan Securities LLC |

---

---

| | |
|:---|:---|
| Address for Notices, etc.: | c/o<br> Morgan Stanley & Co. LLC<br> 1585 Broadway, 29th Floor<br> New York, New York 10036<br> Attn: Investment Banking Division (fax: (212) 507-8999)<br>BofA Securities, Inc<br> 114 West 47th Street<br> NY8-114-07-01<br> New York, NY10036<br> Attention: High Grade Debt Capital Markets Transaction Management/Legal<br> Fax: 212-901-7881 |

---

**SCHEDULE II-C**

---

| | |
|:---|:---|
| **Title of Notes:** | 4.000% Notes due 2031 (the "2031 Notes") |
| **Aggregate principal amount:** | $2500000000 |
| **Pricing Effective Time:** | 5:10 p.m., New York City time, February 23, 2026 |
| **Price to Public:** | 99.855% of the principal amount of the 2031 Notes, plus accrued interest from March 9, 2026 (if any). |
| **Purchase Price by Underwriters:** | 99.505% of the principal amount of the 2031 Notes, plus accrued interest from March 9, 2026 (if any). |
| **Method of and specified funds for payment of purchase price:** | By wire transfer to a bank account specified by the Company in immediately available funds |
| **Indenture:** | Indenture, dated as of March 10, 2015, between the Company and U.S. Bank National Association, as Trustee |
| **Maturity:** | March 15, 2031 |
| **Interest Rate:** | 4.000% |
| **Interest Payment Dates:** | Semiannually on March 15 and September 15, commencing September 15, 2026. |
| **Redemption Provisions:** | As set forth in the Prospectus Supplement under "Description of Notes" |
| **Sinking Fund Provisions:** | No sinking fund provisions |
| **Defeasance provisions:** | Sections 13.2 and 13.3 of the Indenture shall be applicable to the 2031 Notes |
| **Time of Delivery:** | March 9, 2026 |
| **Closing Location for Delivery of Securities:** | The Depository Trust Company<br> 55 Water Street<br> New York, New York 10041 |
| **Names and addresses of Representatives:** |  |
| Designated Representatives: | Morgan Stanley & Co. LLC<br> Barclays Capital Inc.<br> BofA Securities, Inc.<br> J.P. Morgan Securities LLC |

---

---

| | |
|:---|:---|
| Address for Notices, etc.: | c/o<br> Morgan Stanley & Co. LLC<br> 1585 Broadway, 29th Floor<br> New York, New York 10036<br> Attn: Investment Banking Division (fax: (212) 507-8999)<br>BofA Securities, Inc<br> 114 West 47th Street<br> NY8-114-07-01<br> New York, NY10036<br> Attention: High Grade Debt Capital Markets Transaction Management/Legal<br> Fax: 212-901-7881 |

---

**SCHEDULE II-D**

---

| | |
|:---|:---|
| **Title of Notes:** | 4.300% Notes due 2033 (the "2033 Notes") |
| **Aggregate principal amount:** | $2750000000 |
| **Pricing Effective Time:** | 5:10 p.m., New York City time, February 23, 2026 |
| **Price to Public:** | 99.813% of the principal amount of the 2033 Notes, plus accrued interest from March 9, 2026 (if any). |
| **Purchase Price by Underwriters:** | 99.413% of the principal amount of the 2033 Notes, plus accrued interest from March 9, 2026 (if any). |
| **Method of and specified funds for payment of purchase price:** | By wire transfer to a bank account specified by the Company in immediately available funds |
| **Indenture:** | Indenture, dated as of March 10, 2015, between the Company and U.S. Bank National Association, as Trustee |
| **Maturity:** | March 15, 2033 |
| **Interest Rate:** | 4.300% |
| **Interest Payment Dates:** | Semiannually on March 15 and September 15, commencing September 15, 2026. |
| **Redemption Provisions:** | As set forth in the Prospectus Supplement under "Description of Notes" |
| **Sinking Fund Provisions:** | No sinking fund provisions |
| **Defeasance provisions:** | Sections 13.2 and 13.3 of the Indenture shall be applicable to the 2033 Notes |
| **Time of Delivery:** | March 9, 2026 |
| **Closing Location for Delivery of Securities:** | The Depository Trust Company<br> 55 Water Street<br> New York, New York 10041 |
| **Names and addresses of Representatives:** |  |
| Designated Representatives: | Morgan Stanley & Co. LLC<br> Barclays Capital Inc.<br> BofA Securities, Inc.<br> J.P. Morgan Securities LLC |

---

---

| | |
|:---|:---|
| Address for Notices, etc.: | c/o<br> Morgan Stanley & Co. LLC<br> 1585 Broadway, 29th Floor<br> New York, New York 10036<br> Attn: Investment Banking Division (fax: (212) 507-8999)<br>BofA Securities, Inc<br> 114 West 47th Street<br> NY8-114-07-01<br> New York, NY10036<br> Attention: High Grade Debt Capital Markets Transaction Management/Legal<br> Fax: 212-901-7881 |

---

**SCHEDULE II-E**

---

| | |
|:---|:---|
| **Title of Notes:** | 4.650% Notes due 2036 (the "2036 Notes") |
| **Aggregate principal amount:** | $3750000000 |
| **Pricing Effective Time:** | 5:10 p.m., New York City time, February 23, 2026 |
| **Price to Public:** | 99.753% of the principal amount of the 2036 Notes, plus accrued interest from March 9, 2026 (if any). |
| **Purchase Price by Underwriters:** | 99.303% of the principal amount of the 2036 Notes, plus accrued interest from March 9, 2026 (if any). |
| **Method of and specified funds for payment of purchase price:** | By wire transfer to a bank account specified by the Company in immediately available funds |
| **Indenture:** | Indenture, dated as of March 10, 2015, between the Company and U.S. Bank National Association, as Trustee |
| **Maturity:** | March 15, 2036 |
| **Interest Rate:** | 4.650% |
| **Interest Payment Dates:** | Semiannually on March 15 and September 15, commencing September 15, 2026. |
| **Redemption Provisions:** | As set forth in the Prospectus Supplement under "Description of Notes" |
| **Sinking Fund Provisions:** | No sinking fund provisions |
| **Defeasance provisions:** | Sections 13.2 and 13.3 of the Indenture shall be applicable to the 2036 Notes |
| **Time of Delivery:** | March 9, 2026 |
| **Closing Location for Delivery of Securities:** | The Depository Trust Company<br> 55 Water Street<br> New York, New York 10041 |
| **Names and addresses of Representatives:** |  |
| Designated Representatives: | Morgan Stanley & Co. LLC<br> Barclays Capital Inc.<br> BofA Securities, Inc.<br> J.P. Morgan Securities LLC |

---

---

| | |
|:---|:---|
| Address for Notices, etc.: | c/o<br> Morgan Stanley & Co. LLC<br> 1585 Broadway, 29th Floor<br> New York, New York 10036<br> Attn: Investment Banking Division (fax: (212) 507-8999)<br>BofA Securities, Inc<br> 114 West 47th Street<br> NY8-114-07-01<br> New York, NY10036<br> Attention: High Grade Debt Capital Markets Transaction Management/Legal<br> Fax: 212-901-7881 |

---

**SCHEDULE II-F**

---

| | |
|:---|:---|
| **Title of Notes:** | 4.750% Notes due 2038 (the "2038 Notes") |
| **Aggregate principal amount:** | $2000000000 |
| **Pricing Effective Time:** | 5:10 p.m., New York City time, February 23, 2026 |
| **Price to Public:** | 99.718% of the principal amount of the 2038 Notes, plus accrued interest from March 9, 2026 (if any). |
| **Purchase Price by Underwriters:** | 99.243% of the principal amount of the 2038 Notes, plus accrued interest from March 9, 2026 (if any). |
| **Method of and specified funds for payment of purchase price:** | By wire transfer to a bank account specified by the Company in immediately available funds |
| **Indenture:** | Indenture, dated as of March 10, 2015, between the Company and U.S. Bank National Association, as Trustee |
| **Maturity:** | March 15, 2038 |
| **Interest Rate:** | 4.750% |
| **Interest Payment Dates:** | Semiannually on March 15 and September 15, commencing September 15, 2026. |
| **Redemption Provisions:** | As set forth in the Prospectus Supplement under "Description of Notes" |
| **Sinking Fund Provisions:** | No sinking fund provisions |
| **Defeasance provisions:** | Sections 13.2 and 13.3 of the Indenture shall be applicable to the 2038 Notes |
| **Time of Delivery:** | March 9, 2026 |
| **Closing Location for Delivery of Securities:** | The Depository Trust Company<br> 55 Water Street<br> New York, New York 10041 |
| **Names and addresses of Representatives:** |  |
| Designated Representatives: | Morgan Stanley & Co. LLC<br> Barclays Capital Inc.<br> BofA Securities, Inc.<br> J.P. Morgan Securities LLC |

---

---

| | |
|:---|:---|
| Address for Notices, etc.: | c/o<br> Morgan Stanley & Co. LLC<br> 1585 Broadway, 29th Floor<br> New York, New York 10036<br> Attn: Investment Banking Division (fax: (212) 507-8999)<br>BofA Securities, Inc<br> 114 West 47th Street<br> NY8-114-07-01<br> New York, NY10036<br> Attention: High Grade Debt Capital Markets Transaction Management/Legal<br> Fax: 212-901-7881 |

---

**SCHEDULE II-G**

---

| | |
|:---|:---|
| **Title of Notes:** | 5.500% Notes due 2056 (the "2056 Notes") |
| **Aggregate principal amount:** | $3750000000 |
| **Pricing Effective Time:** | 5:10 p.m., New York City time, February 23, 2026 |
| **Price to Public:** | 99.882% of the principal amount of the 2056 Notes, plus accrued interest from March 9, 2026 (if any). |
| **Purchase Price by Underwriters:** | 99.007% of the principal amount of the 2056 Notes, plus accrued interest from March 9, 2026 (if any). |
| **Method of and specified funds for payment of purchase price:** | By wire transfer to a bank account specified by the Company in immediately available funds |
| **Indenture:** | Indenture, dated as of March 10, 2015, between the Company and U.S. Bank National Association, as Trustee |
| **Maturity:** | March 15, 2056 |
| **Interest Rate:** | 5.500% |
| **Interest Payment Dates:** | Semiannually on March 15 and September 15, commencing September 15, 2026. |
| **Redemption Provisions:** | As set forth in the Prospectus Supplement under "Description of Notes" |
| **Sinking Fund Provisions:** | No sinking fund provisions |
| **Defeasance provisions:** | Sections 13.2 and 13.3 of the Indenture shall be applicable to the 2056 Notes |
| **Time of Delivery:** | March 9, 2026 |
| **Closing Location for Delivery of Securities:** | The Depository Trust Company<br> 55 Water Street<br> New York, New York 10041 |
| **Names and addresses of Representatives:** |  |
| Designated Representatives: | Morgan Stanley & Co. LLC<br> Barclays Capital Inc.<br> BofA Securities, Inc.<br> J.P. Morgan Securities LLC |

---

---

| | |
|:---|:---|
| Address for Notices, etc.: | c/o<br> Morgan Stanley & Co. LLC<br> 1585 Broadway, 29th Floor<br> New York, New York 10036<br> Attn: Investment Banking Division (fax: (212) 507-8999)<br>BofA Securities, Inc<br> 114 West 47th Street<br> NY8-114-07-01<br> New York, NY10036<br> Attention: High Grade Debt Capital Markets Transaction Management/Legal<br> Fax: 212-901-7881 |

---

**SCHEDULE II-H**

---

| | |
|:---|:---|
| **Title of Notes:** | 5.600% Notes due 2066 (the "2066 Notes") |
| **Aggregate principal amount:** | $2000000000 |
| **Pricing Effective Time:** | 5:10 p.m., New York City time, February 23, 2026 |
| **Price to Public:** | 99.872% of the principal amount of the 2066 Notes, plus accrued interest from March 9, 2026 (if any). |
| **Purchase Price by Underwriters:** | 98.997% of the principal amount of the 2066 Notes, plus accrued interest from March 9, 2026 (if any). |
| **Method of and specified funds for payment of purchase price:** | By wire transfer to a bank account specified by the Company in immediately available funds |
| **Indenture:** | Indenture, dated as of March 10, 2015, between the Company and U.S. Bank National Association, as Trustee |
| **Maturity:** | March 15, 2066 |
| **Interest Rate:** | 5.600% |
| **Interest Payment Dates:** | Semiannually on March 15 and September 15, commencing September 15, 2026. |
| **Redemption Provisions:** | As set forth in the Prospectus Supplement under "Description of Notes" |
| **Sinking Fund Provisions:** | No sinking fund provisions |
| **Defeasance provisions:** | Sections 13.2 and 13.3 of the Indenture shall be applicable to the 2066 Notes |
| **Time of Delivery:** | March 9, 2026 |
| **Closing Location for Delivery of Securities:** | The Depository Trust Company<br> 55 Water Street<br> New York, New York 10041 |
| **Names and addresses of Representatives:** |  |
| Designated Representatives: | Morgan Stanley & Co. LLC<br> Barclays Capital Inc.<br> BofA Securities, Inc.<br> J.P. Morgan Securities LLC |

---

---

| | |
|:---|:---|
| Address for Notices, etc.: | c/o<br> Morgan Stanley & Co. LLC<br> 1585 Broadway, 29th Floor<br> New York, New York 10036<br> Attn: Investment Banking Division (fax: (212) 507-8999)<br>BofA Securities, Inc<br> 114 West 47th Street<br> NY8-114-07-01<br> New York, NY10036<br> Attention: High Grade Debt Capital Markets Transaction Management/Legal<br> Fax: 212-901-7881 |

---

**SCHEDULE III**

1. Each term sheet set forth in the form of Schedule IV hereto.

**SCHEDULE IV-A**

FINAL TERM SHEET

Floating Rate Notes due 2029

---

| | |
|:---|:---|
| Issuer: | Abbott Laboratories |
| Principal Amount: | $1000000000 |
| Interest: | The Floating Rate Notes will bear interest at a floating rate equal to a benchmark rate, which will initially be Compounded SOFR (as defined in the Prospectus Supplement under "Description of Notes"), plus a spread of 0.500% per year, accruing from March 9, 2026. |
| Maturity: | March 9, 2029 |
| Price to Public: | 100.000% plus accrued interest, if any, from March 9, 2026 |
| Interest Rate Basis: | Compounded SOFR |
| Spread to Compounded SOFR: | +50 bps |
| Interest Payment Dates: | Each March 9, June 9, September 9 and December 9, commencing June 9, 2026 |
| Interest Payment Determination Date: | The date that is two U.S. Government Securities Business Days before each interest payment date. |
| Interest Period: | The period from, and including, the most recent interest payment date for the Floating Rate Notes (or, with respect to the initial interest period only, from and including March 9, 2026) to, but excluding, the next succeeding interest payment date for the Floating Rate Notes, or in the case of the last such period, from, and including, the interest payment date for the Floating Rate Notes immediately preceding the maturity date to, but excluding, the maturity date. |
| Observation Period: | In respect of each interest period, the period from, and including, the date that is two U.S. Government Securities Business Days preceding the first date in such interest period to, but excluding, the Interest Payment Determination Date for such interest period. |
| Settlement Date: | March 9, 2026 |

---

---

| | |
|:---|:---|
| Optional Redemption Provisions: | The Floating Rate Notes are not redeemable prior to maturity, with the exception of a Special Mandatory Redemption. |
| Special Mandatory Redemption Provisions: | As described in the Preliminary Prospectus Supplement dated February 23, 2026. |
| CUSIP: | 002824 BY5 |
| Joint Bookrunning Managers: | Morgan Stanley & Co. LLC<br> Barclays Capital Inc.<br> BofA Securities, Inc.<br> J.P. Morgan Securities LLC<br> Citigroup Global Markets Inc. |
| Co-Managers: | BNP Paribas Securities Corp.<br> Deutsche Bank Securities Inc.<br> MUFG Securities Americas Inc.<br> SG Americas Securities, LLC<br> HSBC Securities (USA) Inc.<br> Mizuho Securities USA LLC<br> Santander US Capital Markets LLC<br> Standard Chartered Bank<br> Goldman Sachs & Co. LLC<br> RBC Capital Markets, LLC<br> Siebert Williams Shank & Co., LLC<br> Academy Securities, Inc.<br> BBVA Securities Inc.<br> ING Financial Markets LLC<br> U.S. Bancorp Investments, Inc. |
| Calculation Agent: | U.S. Bank Trust Company, National Association |

---

**The issuer has filed a registration statement (including a prospectus) with the Commission for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the Commission for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the Commission website at www.sec.gov. Alternatively, the issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by calling Morgan Stanley & Co. LLC, toll-free at (866) 718-1649, Barclays Capital Inc. at (888) 603-5847, BofA Securities, Inc. toll-free at 1-800-294-1322 or J.P. Morgan Securities LLC collect at (212) 834-4533.**

**The issuer expects to deliver the notes against payment for the notes on or about March 9, 2026, which will be the tenth business day following the date of the pricing of the notes. Under Rule 15c6-1 of the Exchange Act, trades in the secondary market generally are required to settle in one business day, unless the parties to a trade expressly agree otherwise. Accordingly, purchasers who wish to trade their notes prior to the business day before the delivery of the notes hereunder will be required, by virtue of the fact that the notes initially will settle in T+10, to specify alternative settlement arrangements to prevent a failed settlement.**

**SCHEDULE IV-B**

FINAL TERM SHEET

3.700% Notes due 2029

---

| | |
|:---|:---|
| Issuer: | Abbott Laboratories |
| Principal Amount: | $2250000000 |
| Coupon: | 3.700% |
| Maturity: | March 9, 2029 |
| Price to Public: | 99.873% plus accrued interest, if any, from March 9, 2026 |
| Yield to maturity: | 3.745% |
| Benchmark Treasury: | 3.500% due February 15, 2029 |
| Spread to Benchmark Treasury: | +30 bps |
| Treasury Price and Yield: | 100-04 7/8 / 3.445% |
| Coupon Dates: | Semiannually on March 9 and September 9 |
| First Coupon: | September 9, 2026 |
| Settlement Date: | March 9, 2026 |
| Par Call Date: | February 9, 2029 |
| Optional Redemption Provisions: | Abbott may redeem the notes at any time prior to the Par Call Date in whole or in part, in each case at Abbott's option, at a redemption price (expressed as a percentage of principal amount and rounded to three decimal places) equal to the sum of: the greater of (1) 100% of the principal amount of the notes being redeemed, or (2) the sum of the present values of the remaining scheduled payments (through the Par Call Date assuming for such purpose the notes matured on the Par Call Date) of principal and interest on the notes being redeemed (exclusive of interest accrued to the redemption date), discounted to the redemption date on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at a rate equal to the Treasury Rate plus 5 basis points, plus, in either case, accrued and unpaid interest, if any, to, but excluding, the redemption date on the principal amount of the notes being redeemed.<br>|

---

---

| | |
|:---|:---|
|  | In addition, Abbott may redeem the notes at any time on or after the Par Call Date in whole or in part, in each case at Abbott's option, at a redemption price equal to 100% of the principal amount of the notes to be redeemed plus accrued and unpaid interest, if any, to, but excluding, the redemption date. |
| Special Mandatory Redemption Provisions: | As described in the Preliminary Prospectus Supplement dated February 23, 2026. |
| CUSIP: | 002824 BR0 |
| Joint Bookrunning Managers: | Morgan Stanley & Co. LLC<br> Barclays Capital Inc.<br> BofA Securities, Inc.<br> J.P. Morgan Securities LLC<br> Citigroup Global Markets Inc. |
| Co-Managers: | BNP Paribas Securities Corp.<br> Deutsche Bank Securities Inc.<br> MUFG Securities Americas Inc.<br> SG Americas Securities, LLC<br> HSBC Securities (USA) Inc.<br> Mizuho Securities USA LLC<br> Santander US Capital Markets LLC<br> Standard Chartered Bank<br> Goldman Sachs & Co. LLC<br> RBC Capital Markets, LLC<br> Siebert Williams Shank & Co., LLC<br> Academy Securities, Inc.<br> BBVA Securities Inc.<br> ING Financial Markets LLC<br> U.S. Bancorp Investments, Inc. |

---

**The issuer has filed a registration statement (including a prospectus) with the Commission for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the Commission for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the Commission website at www.sec.gov. Alternatively, the issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by calling Morgan Stanley & Co. LLC, toll-free at (866) 718-1649, Barclays Capital Inc. at (888) 603-5847, BofA Securities, Inc. toll-free at 1-800-294-1322 or J.P. Morgan Securities LLC collect at (212) 834-4533.**

**The issuer expects to deliver the notes against payment for the notes on or about March 9, 2026, which will be the tenth business day following the date of the pricing of the notes. Under Rule 15c6-1 of the Exchange Act, trades in the secondary market generally are required to settle in one business day, unless the parties to a trade expressly agree otherwise. Accordingly, purchasers who wish to trade their notes prior to the business day before the delivery of the notes hereunder will be required, by virtue of the fact that the notes initially will settle in T+10, to specify alternative settlement arrangements to prevent a failed settlement.**

**SCHEDULE IV-C**

FINAL TERM SHEET

4.000% Notes due 2031

---

| | |
|:---|:---|
| Issuer: | Abbott Laboratories |
| Principal Amount: | $2500000000 |
| Coupon: | 4.000% |
| Maturity: | March 15, 2031 |
| Price to Public: | 99.855% plus accrued interest, if any, from March 9, 2026 |
| Yield to maturity: | 4.032% |
| Benchmark Treasury: | 3.750% due January 31, 2031 |
| Spread to Benchmark Treasury: | +45 bps |
| Treasury Price and Yield: | 100-24 / 3.582% |
| Coupon Dates: | Semiannually on March 15 and September 15 |
| First Coupon: | September 15, 2026 |
| Settlement Date: | March 9, 2026 |
| Par Call Date: | February 15, 2031 |
| Optional Redemption Provisions: | Abbott may redeem the notes at any time prior to the Par Call Date in whole or in part, in each case at Abbott's option, at a redemption price (expressed as a percentage of principal amount and rounded to three decimal places) equal to the sum of: the greater of (1) 100% of the principal amount of the notes being redeemed, or (2) the sum of the present values of the remaining scheduled payments (through the Par Call Date assuming for such purpose the notes matured on the Par Call Date) of principal and interest on the notes being redeemed (exclusive of interest accrued to the redemption date), discounted to the redemption date on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at a rate equal to the Treasury Rate plus 10 basis points, plus, in either case, accrued and unpaid interest, if any, to, but excluding, the redemption date on the principal amount of the notes being redeemed.<br>|

---

---

| | |
|:---|:---|
|  | In addition, Abbott may redeem the notes at any time on or after the Par Call Date in whole or in part, in each case at Abbott's option, at a redemption price equal to 100% of the principal amount of the notes to be redeemed plus accrued and unpaid interest, if any, to, but excluding, the redemption date. |
| Special Mandatory Redemption Provisions: | As described in the Preliminary Prospectus Supplement dated February 23, 2026. |
| CUSIP: | 002824 BS8 |
| Joint Bookrunning Managers: | Morgan Stanley & Co. LLC<br> Barclays Capital Inc.<br> BofA Securities, Inc.<br> J.P. Morgan Securities LLC<br> BNP Paribas Securities Corp.<br>|
| Co-Managers: | Citigroup Global Markets Inc.<br> Deutsche Bank Securities Inc.<br> MUFG Securities Americas Inc.<br> SG Americas Securities, LLC<br> HSBC Securities (USA) Inc.<br> Mizuho Securities USA LLC<br> Santander US Capital Markets LLC<br> Standard Chartered Bank<br> Goldman Sachs & Co. LLC<br> RBC Capital Markets, LLC<br> Siebert Williams Shank & Co., LLC<br> Academy Securities, Inc.<br> BBVA Securities Inc.<br> ING Financial Markets LLC<br> U.S. Bancorp Investments, Inc. |

---

**The issuer has filed a registration statement (including a prospectus) with the Commission for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the Commission for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the Commission website at www.sec.gov. Alternatively, the issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by calling Morgan Stanley & Co. LLC, toll-free at (866) 718-1649, Barclays Capital Inc. at (888) 603-5847, BofA Securities, Inc. toll-free at 1-800-294-1322 or J.P. Morgan Securities LLC collect at (212) 834-4533.**

**The issuer expects to deliver the notes against payment for the notes on or about March 9, 2026, which will be the tenth business day following the date of the pricing of the notes. Under Rule 15c6-1 of the Exchange Act, trades in the secondary market generally are required to settle in one business day, unless the parties to a trade expressly agree otherwise. Accordingly, purchasers who wish to trade their notes prior to the business day before the delivery of the notes hereunder will be required, by virtue of the fact that the notes initially will settle in T+10, to specify alternative settlement arrangements to prevent a failed settlement.**

**SCHEDULE IV-D**

FINAL TERM SHEET

4.300% Notes due 2033

---

| | |
|:---|:---|
| Issuer: | Abbott Laboratories |
| Principal Amount: | $2750000000 |
| Coupon: | 4.300% |
| Maturity: | March 15, 2033 |
| Price to Public: | 99.813% plus accrued interest, if any, from March 9, 2026 |
| Yield to maturity: | 4.331% |
| Benchmark Treasury: | 4.000% due January 31, 2033 |
| Spread to Benchmark Treasury: | +55 bps |
| Treasury Price and Yield: | 101-10 1/4 / 3.781% |
| Coupon Dates: | Semiannually on March 15 and September 15 |
| First Coupon: | September 15, 2026 |
| Settlement Date: | March 9, 2026 |
| Par Call Date: | January 15, 2033 |
| Optional Redemption Provisions: | Abbott may redeem the notes at any time prior to the Par Call Date in whole or in part, in each case at Abbott's option, at a redemption price (expressed as a percentage of principal amount and rounded to three decimal places) equal to the sum of: the greater of (1) 100% of the principal amount of the notes being redeemed, or (2) the sum of the present values of the remaining scheduled payments (through the Par Call Date assuming for such purpose the notes matured on the Par Call Date) of principal and interest on the notes being redeemed (exclusive of interest accrued to the redemption date), discounted to the redemption date on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at a rate equal to the Treasury Rate plus 10 basis points, plus, in either case, accrued and unpaid interest, if any, to, but excluding, the redemption date on the principal amount of the notes being redeemed. |

---

---

| | |
|:---|:---|
|  | In addition, Abbott may redeem the notes at any time on or after the Par Call Date in whole or in part, in each case at Abbott's option, at a redemption price equal to 100% of the principal amount of the notes to be redeemed plus accrued and unpaid interest, if any, to, but excluding, the redemption date. |
| Special Mandatory Redemption Provisions: | As described in the Preliminary Prospectus Supplement dated February 23, 2026. |
| CUSIP: | 002824 BT6 |
| Joint Bookrunning Managers: | Morgan Stanley & Co. LLC<br> Barclays Capital Inc.<br> BofA Securities, Inc.<br> J.P. Morgan Securities LLC<br> MUFG Securities Americas Inc. |
| Co-Managers: | BNP Paribas Securities Corp.<br> Citigroup Global Markets Inc.<br> Deutsche Bank Securities Inc.<br> SG Americas Securities, LLC<br> HSBC Securities (USA) Inc.<br> Mizuho Securities USA LLC<br> Santander US Capital Markets LLC<br> Standard Chartered Bank<br> Goldman Sachs & Co. LLC<br> RBC Capital Markets, LLC<br> Siebert Williams Shank & Co., LLC<br> Academy Securities, Inc.<br> BBVA Securities Inc.<br> ING Financial Markets LLC<br> U.S. Bancorp Investments, Inc. |

---

**The issuer has filed a registration statement (including a prospectus) with the Commission for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the Commission for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the Commission website at www.sec.gov. Alternatively, the issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by calling Morgan Stanley & Co. LLC, toll-free at (866) 718-1649, Barclays Capital Inc. at (888) 603-5847, BofA Securities, Inc. toll-free at 1-800-294-1322 or J.P. Morgan Securities LLC collect at (212) 834-4533.**

**The issuer expects to deliver the notes against payment for the notes on or about March 9, 2026, which will be the tenth business day following the date of the pricing of the notes. Under Rule 15c6-1 of the Exchange Act, trades in the secondary market generally are required to settle in one business day, unless the parties to a trade expressly agree otherwise. Accordingly, purchasers who wish to trade their notes prior to the business day before the delivery of the notes hereunder will be required, by virtue of the fact that the notes initially will settle in T+10, to specify alternative settlement arrangements to prevent a failed settlement.**

**SCHEDULE IV-E**

FINAL TERM SHEET

4.650% Notes due 2036

---

| | |
|:---|:---|
| Issuer: | Abbott Laboratories |
| Principal Amount: | $3750000000 |
| Coupon: | 4.650% |
| Maturity: | March 15, 2036 |
| Price to Public: | 99.753% plus accrued interest, if any, from March 9, 2026 |
| Yield to maturity: | 4.681% |
| Benchmark Treasury: | 4.125% due February 15, 2036 |
| Spread to Benchmark Treasury: | +65 bps |
| Treasury Price and Yield: | 100-24 + / 4.031% |
| Coupon Dates: | Semiannually on March 15 and September 15 |
| First Coupon: | September 15, 2026 |
| Settlement Date: | March 9, 2026 |
| Par Call Date: | December 15, 2035 |
| Optional Redemption Provisions: | Abbott may redeem the notes at any time prior to the Par Call Date in whole or in part, in each case at Abbott's option, at a redemption price (expressed as a percentage of principal amount and rounded to three decimal places) equal to the sum of: the greater of (1) 100% of the principal amount of the notes being redeemed, or (2) the sum of the present values of the remaining scheduled payments (through the Par Call Date assuming for such purpose the notes matured on the Par Call Date) of principal and interest on the notes being redeemed (exclusive of interest accrued to the redemption date), discounted to the redemption date on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at a rate equal to the Treasury Rate plus 10 basis points, plus, in either case, accrued and unpaid interest, if any, to, but excluding, the redemption date on the principal amount of the notes being redeemed.<br>|

---

---

| | |
|:---|:---|
|  | In addition, Abbott may redeem the notes at any time on or after the Par Call Date in whole or in part, in each case at Abbott's option, at a redemption price equal to 100% of the principal amount of the notes to be redeemed plus accrued and unpaid interest, if any, to, but excluding, the redemption date. |
| Special Mandatory Redemption Provisions: | As described in the Preliminary Prospectus Supplement dated February 23, 2026. |
| CUSIP: | 002824 BU3 |
| Joint Bookrunning Managers: | Morgan Stanley & Co. LLC<br> Barclays Capital Inc.<br> BofA Securities, Inc.<br> J.P. Morgan Securities LLC<br> SG Americas Securities, LLC |
| Co-Managers: | BNP Paribas Securities Corp.<br> Citigroup Global Markets Inc.<br> Deutsche Bank Securities Inc.<br> MUFG Securities Americas Inc.<br> HSBC Securities (USA) Inc.<br> Mizuho Securities USA LLC<br> Santander US Capital Markets LLC<br> Standard Chartered Bank<br> Goldman Sachs & Co. LLC<br> RBC Capital Markets, LLC<br> Siebert Williams Shank & Co., LLC<br> Academy Securities, Inc.<br> BBVA Securities Inc.<br> ING Financial Markets LLC<br> U.S. Bancorp Investments, Inc. |

---

**The issuer has filed a registration statement (including a prospectus) with the Commission for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the Commission for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the Commission website at www.sec.gov. Alternatively, the issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by calling Morgan Stanley & Co. LLC, toll-free at (866) 718-1649, Barclays Capital Inc. at (888) 603-5847, BofA Securities, Inc. toll-free at 1-800-294-1322 or J.P. Morgan Securities LLC collect at (212) 834-4533.**

**The issuer expects to deliver the notes against payment for the notes on or about March 9, 2026, which will be the tenth business day following the date of the pricing of the notes. Under Rule 15c6-1 of the Exchange Act, trades in the secondary market generally are required to settle in one business day, unless the parties to a trade expressly agree otherwise. Accordingly, purchasers who wish to trade their notes prior to the business day before the delivery of the notes hereunder will be required, by virtue of the fact that the notes initially will settle in T+10, to specify alternative settlement arrangements to prevent a failed settlement.**

**SCHEDULE IV-F**

FINAL TERM SHEET

4.750% Notes due 2038

---

| | |
|:---|:---|
| Issuer: | Abbott Laboratories |
| Principal Amount: | $2000000000 |
| Coupon: | 4.750% |
| Maturity: | March 15, 2038 |
| Price to Public: | 99.718% plus accrued interest, if any, from March 9, 2026 |
| Yield to maturity: | 4.781% |
| Benchmark Treasury: | 4.125% due February 15, 2036 |
| Spread to Benchmark Treasury: | +75 bps |
| Treasury Price and Yield: | 100-24 + / 4.031% |
| Coupon Dates: | Semiannually on March 15 and September 15 |
| First Coupon: | September 15, 2026 |
| Settlement Date: | March 9, 2026 |
| Par Call Date: | December 15, 2037 |
| Optional Redemption Provisions: | Abbott may redeem the notes at any time prior to the Par Call Date in whole or in part, in each case at Abbott's option, at a redemption price (expressed as a percentage of principal amount and rounded to three decimal places) equal to the sum of: the greater of (1) 100% of the principal amount of the notes being redeemed, or (2) the sum of the present values of the remaining scheduled payments (through the Par Call Date assuming for such purpose the notes matured on the Par Call Date) of principal and interest on the notes being redeemed (exclusive of interest accrued to the redemption date), discounted to the redemption date on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at a rate equal to the Treasury Rate plus 15 basis points, plus, in either case, accrued and unpaid interest, if any, to, but excluding, the redemption date on the principal amount of the notes being redeemed.<br>|

---

---

| | |
|:---|:---|
|  | In addition, Abbott may redeem the notes at any time on or after the Par Call Date in whole or in part, in each case at Abbott's option, at a redemption price equal to 100% of the principal amount of the notes to be redeemed plus accrued and unpaid interest, if any, to, but excluding, the redemption date. |
| Special Mandatory Redemption Provisions: | As described in the Preliminary Prospectus Supplement dated February 23, 2026. |
| CUSIP: | 002824 BV1 |
| Joint Bookrunning Managers: | Morgan Stanley & Co. LLC<br> Barclays Capital Inc.<br> BofA Securities, Inc.<br> J.P. Morgan Securities LLC<br> BNP Paribas Securities Corp. |
| Co-Managers: | Citigroup Global Markets Inc.<br> Deutsche Bank Securities Inc.<br> MUFG Securities Americas Inc.<br> SG Americas Securities, LLC<br> HSBC Securities (USA) Inc.<br> Mizuho Securities USA LLC<br> Santander US Capital Markets LLC<br> Standard Chartered Bank<br> Goldman Sachs & Co. LLC<br> RBC Capital Markets, LLC<br> Siebert Williams Shank & Co., LLC<br> Academy Securities, Inc.<br> BBVA Securities Inc.<br> ING Financial Markets LLC<br> U.S. Bancorp Investments, Inc. |

---

**The issuer has filed a registration statement (including a prospectus) with the Commission for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the Commission for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the Commission website at www.sec.gov. Alternatively, the issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by calling Morgan Stanley & Co. LLC, toll-free at (866) 718-1649, Barclays Capital Inc. at (888) 603-5847, BofA Securities, Inc. toll-free at 1-800-294-1322 or J.P. Morgan Securities LLC collect at (212) 834-4533.**

**The issuer expects to deliver the notes against payment for the notes on or about March 9, 2026, which will be the tenth business day following the date of the pricing of the notes. Under Rule 15c6-1 of the Exchange Act, trades in the secondary market generally are required to settle in one business day, unless the parties to a trade expressly agree otherwise. Accordingly, purchasers who wish to trade their notes prior to the business day before the delivery of the notes hereunder will be required, by virtue of the fact that the notes initially will settle in T+10, to specify alternative settlement arrangements to prevent a failed settlement.**

**SCHEDULE IV-G**

FINAL TERM SHEET

5.500% Notes due 2056

---

| | |
|:---|:---|
| Issuer: | Abbott Laboratories |
| Principal Amount: | $3750000000 |
| Coupon: | 5.500% |
| Maturity: | March 15, 2056 |
| Price to Public: | 99.882% plus accrued interest, if any, from March 9, 2026 |
| Yield to maturity: | 5.508% |
| Benchmark Treasury: | 4.625% due November 15, 2055 |
| Spread to Benchmark Treasury: | +80 bps |
| Treasury Price and Yield: | 98-21 + / 4.708% |
| Coupon Dates: | Semiannually on March 15 and September 15 |
| First Coupon: | September 15, 2026 |
| Settlement Date: | March 9, 2026 |
| Par Call Date: | September 15, 2055 |
| Optional Redemption Provisions: | Abbott may redeem the notes at any time prior to the Par Call Date in whole or in part, in each case at Abbott's option, at a redemption price (expressed as a percentage of principal amount and rounded to three decimal places) equal to the sum of: the greater of (1) 100% of the principal amount of the notes being redeemed, or (2) the sum of the present values of the remaining scheduled payments (through the Par Call Date assuming for such purpose the notes matured on the Par Call Date) of principal and interest on the notes being redeemed (exclusive of interest accrued to the redemption date), discounted to the redemption date on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at a rate equal to the Treasury Rate plus 15 basis points, plus, in either case, accrued and unpaid interest, if any, to, but excluding, the redemption date on the principal amount of the notes being redeemed.<br>|

---

---

| | |
|:---|:---|
|  | In addition, Abbott may redeem the notes at any time on or after the Par Call Date in whole or in part, in each case at Abbott's option, at a redemption price equal to 100% of the principal amount of the notes to be redeemed plus accrued and unpaid interest, if any, to, but excluding, the redemption date. |
| Special Mandatory Redemption Provisions: | As described in the Preliminary Prospectus Supplement dated February 23, 2026. |
| CUSIP: | 002824 BW9 |
| Joint Bookrunning Managers: | Morgan Stanley & Co. LLC<br> Barclays Capital Inc.<br> BofA Securities, Inc.<br> J.P. Morgan Securities LLC<br> Deutsche Bank Securities Inc.<br>|
| Co-Managers: | BNP Paribas Securities Corp.<br> Citigroup Global Markets Inc.<br> MUFG Securities Americas Inc.<br> SG Americas Securities, LLC<br> HSBC Securities (USA) Inc.<br> Mizuho Securities USA LLC<br> Santander US Capital Markets LLC<br> Standard Chartered Bank<br> Goldman Sachs & Co. LLC<br> RBC Capital Markets, LLC<br> Siebert Williams Shank & Co., LLC<br> Academy Securities, Inc.<br> BBVA Securities Inc.<br> ING Financial Markets LLC<br> U.S. Bancorp Investments, Inc. |

---

**The issuer has filed a registration statement (including a prospectus) with the Commission for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the Commission for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the Commission website at www.sec.gov. Alternatively, the issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by calling Morgan Stanley & Co. LLC, toll-free at (866) 718-1649, Barclays Capital Inc. at (888) 603-5847, BofA Securities, Inc. toll-free at 1-800-294-1322 or J.P. Morgan Securities LLC collect at (212) 834-4533.**

**The issuer expects to deliver the notes against payment for the notes on or about March 9, 2026, which will be the tenth business day following the date of the pricing of the notes. Under Rule 15c6-1 of the Exchange Act, trades in the secondary market generally are required to settle in one business day, unless the parties to a trade expressly agree otherwise. Accordingly, purchasers who wish to trade their notes prior to the business day before the delivery of the notes hereunder will be required, by virtue of the fact that the notes initially will settle in T+10, to specify alternative settlement arrangements to prevent a failed settlement.**

**SCHEDULE IV-H**

FINAL TERM SHEET

5.600% Notes due 2066

---

| | |
|:---|:---|
| Issuer: | Abbott Laboratories |
| Principal Amount: | $2000000000 |
| Coupon: | 5.600% |
| Maturity: | March 15, 2066 |
| Price to Public: | 99.872% plus accrued interest, if any, from March 9, 2026 |
| Yield to maturity: | 5.608% |
| Benchmark Treasury: | 4.625% due November 15, 2055 |
| Spread to Benchmark Treasury: | +90 bps |
| Treasury Price and Yield: | 98-21 + / 4.708% |
| Coupon Dates: | Semiannually on March 15 and September 15 |
| First Coupon: | September 15, 2026 |
| Settlement Date: | March 9, 2026 |
| Par Call Date: | September 15, 2065 |
| Optional Redemption Provisions: | Abbott may redeem the notes at any time prior to the Par Call Date in whole or in part, in each case at Abbott's option, at a redemption price (expressed as a percentage of principal amount and rounded to three decimal places) equal to the sum of: the greater of (1) 100% of the principal amount of the notes being redeemed, or (2) the sum of the present values of the remaining scheduled payments (through the Par Call Date assuming for such purpose the notes matured on the Par Call Date) of principal and interest on the notes being redeemed (exclusive of interest accrued to the redemption date), discounted to the redemption date on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at a rate equal to the Treasury Rate plus 15 basis points, plus, in either case, accrued and unpaid interest, if any, to, but excluding, the redemption date on the principal amount of the notes being redeemed.<br>|

---

---

| | |
|:---|:---|
|  | In addition, Abbott may redeem the notes at any time on or after the Par Call Date in whole or in part, in each case at Abbott's option, at a redemption price equal to 100% of the principal amount of the notes to be redeemed plus accrued and unpaid interest, if any, to, but excluding, the redemption date. |
| Special Mandatory Redemption Provisions: | As described in the Preliminary Prospectus Supplement dated February 23, 2026. |
| CUSIP: | 002824 BX7 |
| Joint Bookrunning Managers: | Morgan Stanley & Co. LLC<br> Barclays Capital Inc.<br> BofA Securities, Inc.<br> J.P. Morgan Securities LLC<br> Citigroup Global Markets Inc.<br>|
| Co-Managers: | BNP Paribas Securities Corp.<br> Deutsche Bank Securities Inc.<br> MUFG Securities Americas Inc.<br> SG Americas Securities, LLC<br> HSBC Securities (USA) Inc.<br> Mizuho Securities USA LLC<br> Santander US Capital Markets LLC<br> Standard Chartered Bank<br> Goldman Sachs & Co. LLC<br> RBC Capital Markets, LLC<br> Siebert Williams Shank & Co., LLC<br> Academy Securities, Inc.<br> BBVA Securities Inc.<br> ING Financial Markets LLC<br> U.S. Bancorp Investments, Inc. |

---

**The issuer has filed a registration statement (including a prospectus) with the Commission for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the Commission for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the Commission website at www.sec.gov. Alternatively, the issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by calling Morgan Stanley & Co. LLC, toll-free at (866) 718-1649, Barclays Capital Inc. at (888) 603-5847, BofA Securities, Inc. toll-free at 1-800-294-1322 or J.P. Morgan Securities LLC collect at (212) 834-4533.**

**The issuer expects to deliver the notes against payment for the notes on or about March 9, 2026, which will be the tenth business day following the date of the pricing of the notes. Under Rule 15c6-1 of the Exchange Act, trades in the secondary market generally are required to settle in one business day, unless the parties to a trade expressly agree otherwise. Accordingly, purchasers who wish to trade their notes prior to the business day before the delivery of the notes hereunder will be required, by virtue of the fact that the notes initially will settle in T+10, to specify alternative settlement arrangements to prevent a failed settlement.**